SCHEMBL950304

SCHEMBL950304

CCC(=O)N(Cc1cccc(C)c1)c1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 17/20 0.68
ALDH1A1 P00352 3/20 0.46
NPC1 O15118 1/20 0.46
JAK2 O60674 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
PAX8 Q06710 1/20 0.46
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
CYP2C8 P10632 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950666 0.90 PTGDR2 (0.67) PTGDR2ALDH1A1NPC1JAK2HTT
SCHEMBL952104 0.90 PTGDR2 (0.60) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL12944596 0.90 PTGDR2 (0.55) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL12944794 0.90 PTGDR2 (0.55) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL952651 0.89 PTGDR2 (0.69) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL950939 0.89 PTGDR2 (0.54) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL12944492 0.87 PTGDR2 (0.58) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL954738 0.87 PTGDR2 (0.52) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL12944575 0.87 PTGDR2 (0.55) PTGDR2CYP2C8CYP2C9CYP2C19
SCHEMBL950639 0.87 PTGDR2 (0.70) PTGDR2ALDH1A1HPGDCYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454243-A2 TETRAZOLE DERIVATIVES Merck Serono SA (CH) 2012-05-23 EP disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 US disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115869-A1 TETRAZOLE DERIVATIVES TSLP, IL5, CMA1 PTGDR2 548/4885ALDH1A1 184/4885NPC1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.